Highlights From The Most Recent Investors Webinar
March 4, 2025
Highlights From The Most Recent Investors Webinar
On February 18, RegenMed’s Co-Founder and Chief Executive Officer Michael P. Tierney, and its Chief Technology and Information Officer, Dolph Courchaine, were interviewed during the final Investors Webinar prior to the conclusion of this investment round. Key segments can be found on the Company’s YouTube channel, with links below. The entire playlist is here.
RegenMed’s leadership and employees extend their deep gratitude to all fellow shareholders for their support. The Company looks forward to an exciting 2025 with continued acceleration of its growth in the fundamentally important world of healthcare data and value-based medicine.
Highlights From The Most Recent Investors Webinar
March 4, 2025
On February 18, RegenMed’s Co-Founder and Chief Executive Officer Michael P. Tierney, and its Chief Technology and Information Officer, Dolph Courchaine, were interviewed during the final Investors Webinar prior to the conclusion of this investment round. Key segments can be found on the Company’s YouTube channel, with links below. The entire playlist is here.
RegenMed’s leadership and employees extend their deep gratitude to all fellow shareholders for their support. The Company looks forward to an exciting 2025 with continued acceleration of its growth in the fundamentally important world of healthcare data and value-based medicine.
𝘛𝘩𝘪𝘴 𝘙𝘦𝘨 𝘊𝘍 𝘰𝘧𝘧𝘦𝘳𝘪𝘯𝘨 𝘪𝘴 𝘮𝘢𝘥𝘦 𝘢𝘷𝘢𝘪𝘭𝘢𝘣𝘭𝘦 𝘵𝘩𝘳𝘰𝘶𝘨𝘩 𝘚𝘵𝘢𝘳𝘵𝘌𝘯𝘨𝘪𝘯𝘦 𝘗𝘳𝘪𝘮𝘢𝘳𝘺 𝘓𝘓𝘊, 𝘮𝘦𝘮𝘣𝘦𝘳 𝘍𝘐𝘕𝘙𝘈/𝘚𝘐𝘗𝘊. 𝘛𝘩𝘪𝘴 𝘪𝘯𝘷𝘦𝘴𝘵𝘮𝘦𝘯𝘵 𝘪𝘴 𝘴𝘱𝘦𝘤𝘶𝘭𝘢𝘵𝘪𝘷𝘦, 𝘪𝘭𝘭𝘪𝘲𝘶𝘪𝘥, 𝘢𝘯𝘥 𝘪𝘯𝘷𝘰𝘭𝘷𝘦𝘴 𝘢 𝘩𝘪𝘨𝘩 𝘥𝘦𝘨𝘳𝘦𝘦 𝘰𝘧 𝘳𝘪𝘴𝘬, 𝘪𝘯𝘤𝘭𝘶𝘥𝘪𝘯𝘨 𝘵𝘩𝘦 𝘱𝘰𝘴𝘴𝘪𝘣𝘭𝘦 𝘭𝘰𝘴𝘴 𝘰𝘧 𝘺𝘰𝘶𝘳 𝘦𝘯𝘵𝘪𝘳𝘦 𝘪𝘯𝘷𝘦𝘴𝘵𝘮𝘦𝘯𝘵. 𝘛𝘩𝘪𝘴 𝘱𝘳𝘦𝘴𝘦𝘯𝘵𝘢𝘵𝘪𝘰𝘯 𝘮𝘢𝘺 𝘤𝘰𝘯𝘵𝘢𝘪𝘯 𝘧𝘰𝘳𝘸𝘢𝘳𝘥-𝘭𝘰𝘰𝘬𝘪𝘯𝘨 𝘴𝘵𝘢𝘵𝘦𝘮𝘦𝘯𝘵𝘴 𝘣𝘢𝘴𝘦𝘥 𝘰𝘯 𝘤𝘶𝘳𝘳𝘦𝘯𝘵 𝘦𝘹𝘱𝘦𝘤𝘵𝘢𝘵𝘪𝘰𝘯𝘴. 𝘈𝘤𝘵𝘶𝘢𝘭 𝘳𝘦𝘴𝘶𝘭𝘵𝘴 𝘤𝘰𝘶𝘭𝘥 𝘥𝘪𝘧𝘧𝘦𝘳 𝘴𝘪𝘨𝘯𝘪𝘧𝘪𝘤𝘢𝘯𝘵𝘭𝘺 𝘥𝘶𝘦 𝘵𝘰 𝘷𝘢𝘳𝘪𝘰𝘶𝘴 𝘳𝘪𝘴𝘬𝘴 𝘢𝘯𝘥 𝘶𝘯𝘤𝘦𝘳𝘵𝘢𝘪𝘯𝘵𝘪𝘦𝘴.